X

Week in Review: The Latest from PhRMA

Priscilla VanderVeer   |     June 5, 2015   |   SHARE THIS

Who is Making Decisions About Your Health? This week, the Catalyst featured key information about fail first and prior authorization processes, which are methods used by health insurers to limit the use of certain prescriptions to control health care costs and steer patients to medicines insurers prefer. Learn more about this and more from AccessBetterCoverage.org, a helpful resource for information, videos and research on health insurance.

week-in-reviewA Look at 340B Purchases: In the latest 340B Spotlight, we debunk a commonly referenced statistic that the 340B program represents only 2 percent of pharmaceutical sales. Learn the facts and see why the number is actually much higher and is expected to rise.

How Medicines Can Curb Health Care Costs: Slowing, treating and curing disease helps patients avoid expensive hospital care, and medicines can be a part of the solution to reducing medical spending. Take a look at the latest video on how continued innovation is not only helping patients live longer, healthier lives, but is also stabilizing the cost of other medical services.

Preventing Prescription Drug Abuse: Experts from across the country gathered in Boston this week to discuss tools for the ongoing battle against prescription drug abuse. PhRMA supported the event, which was hosted by the Network for Excellence in Health Innovation (NEHI) and focused on the creation and use of provider-friendly prescription drug monitoring programs (PDMPs).

Gaps in Quality Measures for Cancer Patients: While this year’s American Society of Clinical Oncology (ASCO) annual meeting featured a lot of announcements about the exciting progress being made in treating cancer, as well as a lot of conversation about “value-based” payment models for cancer care, there remains a tremendous need to close gaps in cancer quality measures to advance these new payment models, according to new research from Avalere Health. Read this Catalyst post for more.

Scientific Advances Fuel Personalized Medicine: We rounded out the week by releasing a new chart pack exploring how advances in the field of personalized medicine (sometimes referred to as precision or individualized medicine) are helping patients. Check it out to learn more about the continued development of these targeted therapies. 

Get instant updates on issues you care about - here. Get Updates

Priscilla VanderVeer

Priscilla VanderVeer Priscilla VanderVeer Priscilla VanderVeer is a vice president, public affairs, at PhRMA. Ms. VanderVeer has more than 15 years of experience communicating important health care issues to a wide variety of audiences, including medical, health and patient advocates; policymakers and opinion-leaders; and the general public. At PhRMA, Ms. VanderVeer leads the development and execution of communications strategies and activities for the organization’s key state advocacy priorities. She lives in Annapolis, Maryland with her husband, Ken and their two dogs: Bea Arthur, a tiny 5 lb. Maltese and Henry, a slightly larger-than-average Yorkshire Terrier.

Topics: Access, Personalized Medicine, 340B, Access Better Coverage

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates